Serum Institute of IndiaSerum Institute of India Pvt. Ltd. Is India’s No. 1 biotechnology company which specializes in manufacturing biologicals that are used in life or death situations. Their state-of-the-art facilities, like genetic technologies, play an important role in producing anti-serums and a plethora of medicines. In 1966, Dr. Cyrus Poonawalla found the Serum Institute of India with a vision of manufacturing biological medications that were usually imported. With the help of Serum Institute, the vaccines for DPT (Diphtheria, Tetanus and Pertussis), Tetanus, Snake Venom and MMR (Measles, Mumps and Rubella) were abundantly available in India at reduced prices. Their progress with Polio, Diptheria and aforementioned diseases at economical prices made them the world’s largest vaccine manufacturer by production and sale of over 1.3 billion medical doses.
Serum Institute is arguable the best medical institute in terms of machinery and technical advancements. Some shining examples of cutting edge machinery includes high-speed vial washing, advanced tunnel systems and manufacturing of polysaccharide vaccines. The fill-stop-seal machinery can work at the speed of 500 containers per minute with an accuracy up to third digit of decimal point. In case of any emergency on a large scale, multiple plants can work in synchronization to produce high number of doses in minimum time span. The facility is constantly upgraded over a period of time and has been accredited by the World Health Organization, Geneva.
Bilthoven Biologicals, Netherlands was the first acquisition of Serum Institute on June 29, 2012. Due to this, the institute became the fourth manufacturer in the world with resources and knowledge of Injectable Polio Vaccines. This deal not only helped to establish a 40-acre large manufacturing base in Europe, but also contributed to a substantial effort of Polio eradication. In 2017, Praha Vaccines, a bio-engineering and pharmaceutical company, was acquired with cGMP aligned production facilities like their previous manufacturing bases.
Serum Institute of India has always aimed at meeting the international standard at feasible prices. Their latest venture, Poonawalla Biotech Park, strives to strengthen the production and manufacturing ability of products like HPV, Rotavirus vaccine, recombinant BCG vaccine, etc. This facility is expected to be up by the end of 2018 and meet the standards of global regulatory agencies.